Citadel Advisors’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,584
| Closed | -$58.8K | – | 13298 |
|
|
2025
Q1 | $58.8K | Buy |
7,584
+2,416
| +47% | +$29K | ﹤0.01% | 12137 |
|
|
2024
Q4 | $68.4K | Buy |
5,168
+304
| +6% | +$2.83K | ﹤0.01% | 12009 |
|
|
2024
Q3 | $48.6K | Buy |
4,864
+1,488
| +44% | +$22.5K | ﹤0.01% | 11948 |
|
|
2024
Q2 | $75.3K | Sell |
3,376
-6,512
| -66% | -$201K | ﹤0.01% | 11279 |
|
|
2024
Q1 | $581K | Buy |
9,888
+7,348
| +289% | +$317K | ﹤0.01% | 8052 |
|
|
2023
Q4 | $56.3K | Sell |
2,540
-68
| -3% | -$1.03K | ﹤0.01% | 11660 |
|
|
2023
Q3 | $56.3K | Sell |
2,608
-16,740
| -87% | -$657K | ﹤0.01% | 11615 |
|
|
2023
Q2 | $1.31M | Buy |
19,348
+17,092
| +758% | +$7.07M | ﹤0.01% | 5922 |
|
|
2023
Q1 | $1.05M | Sell |
2,256
-4,156
| -65% | -$2.2M | ﹤0.01% | 6669 |
|
|
2022
Q4 | $2.57M | Sell |
6,412
-656
| -9% | -$251K | ﹤0.01% | 5018 |
|
|
2022
Q3 | $2.3M | Buy |
7,068
+1,136
| +19% | +$366K | ﹤0.01% | 5326 |
|
|
2022
Q2 | $1.57M | Buy |
5,932
+4,488
| +311% | +$1.15M | ﹤0.01% | 6051 |
|
|
2022
Q1 | $434K | Buy |
1,444
+96
| +7% | +$33.5K | ﹤0.01% | 9723 |
|
|
2021
Q4 | $475K | Sell |
1,348
-1,368
| -50% | -$426K | ﹤0.01% | 9822 |
|
|
2021
Q3 | $694K | Sell |
2,716
-2,076
| -43% | -$736K | ﹤0.01% | 9096 |
|
|
2021
Q2 | $3.19M | Buy |
4,792
+2,736
| +133% | +$1.58M | ﹤0.01% | 5448 |
|
|
2021
Q1 | $1.78M | Sell |
2,056
-2,564
| -55% | -$2.73M | ﹤0.01% | 6678 |
|
|
2020
Q4 | $4.28M | Buy |
4,620
+2,776
| +151% | +$2.92M | ﹤0.01% | 3935 |
|
|
2020
Q3 | $1.9M | Sell |
1,844
-136
| -7% | -$146K | ﹤0.01% | 4815 |
|
|
2020
Q2 | $2.01M | Buy |
1,980
+1,204
| +155% | +$1.12M | ﹤0.01% | 4568 |
|
|
2020
Q1 | $674K | Sell |
776
-580
| -43% | -$577K | ﹤0.01% | 5985 |
|
|
2019
Q4 | $1.45M | Sell |
1,356
-228
| -14% | -$233K | ﹤0.01% | 4924 |
|
|
2019
Q3 | $1.46M | Buy |
1,584
+1,024
| +183% | +$1.12M | ﹤0.01% | 4961 |
|
|
2019
Q2 | $633K | Sell |
560
-2,628
| -82% | -$2.88M | ﹤0.01% | 6444 |
|
|
2019
Q1 | $4.33M | Sell |
3,188
-116
| -4% | -$157K | ﹤0.01% | 3212 |
|
|
2018
Q4 | $3.82M | Buy |
3,304
+2,028
| +159% | +$2.28M | ﹤0.01% | 3181 |
|
|
2018
Q3 | $1.94M | Buy |
1,276
+500
| +64% | +$770K | ﹤0.01% | 4467 |
|
|
2018
Q2 | $1.21M | Buy |
776
+252
| +48% | +$329K | ﹤0.01% | 4881 |
|
|
2018
Q1 | $605K | Sell |
524
-132
| -20% | -$174K | ﹤0.01% | 5575 |
|
|
2017
Q4 | $777K | Sell |
656
-632
| -49% | -$792K | ﹤0.01% | 5018 |
|
|
2017
Q3 | $1.73M | Buy |
1,288
+328
| +34% | +$346K | ﹤0.01% | 3571 |
|
|
2017
Q2 | $775K | Buy |
960
+452
| +89% | +$315K | ﹤0.01% | 4483 |
|
|
2017
Q1 | $313K | Sell |
508
-240
| -32% | -$146K | ﹤0.01% | 5828 |
|
|
2016
Q4 | $400K | Sell |
748
-72
| -9% | -$36K | ﹤0.01% | 5252 |
|
|
2016
Q3 | $424K | Buy |
820
+128
| +18% | +$60.3K | ﹤0.01% | 5113 |
|
|
2016
Q2 | $284K | Buy |
+692
| New | +$317K | ﹤0.01% | 5296 |
|
|
2016
Q1 | – | Sell |
-96
| Closed | -$73K | – | 7132 |
|
|
2015
Q4 | $73K | Sell |
96
-84
| -47% | -$55.7K | ﹤0.01% | 6987 |
|
|
2015
Q3 | $99K | Buy |
+180
| New | +$109K | ﹤0.01% | 6965 |
|
Other funds holding KYNB
AC
VCM
VFT
Citadel Advisors's KYNB Position: Q1 2026 in Review
Citadel Advisors sold out of Kyntra Bio (KYNB) in Q1 2026, closing a stake of 16,756 shares — an estimated $147K sold.
Citadel Advisors first reported a position in KYNB in Q1 2015 and held it in 38 quarters. The position peaked at $33.6M in Q2 2019. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.
- Citadel Advisors reported no remaining Kyntra Bio position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 16,756 Kyntra Bio shares in Q1 2026, an estimated $147K.
- Citadel Advisors first reported a position in Kyntra Bio in Q1 2015 and held it in 38 quarters.
- Citadel Advisors's Kyntra Bio position peaked at $33.6M in Q2 2019.
- 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.